Discuss the regulatory challenges posed by peptide therapeutics and wellness drugs sold online in India. Suggest reforms to the drug-regulatory framework.

Peptides are short chains of amino acids. As medicines they range from approved drugs such as insulin to unproven "recovery" products. In October 2026 the US used an enforcement discretion policy to let six unapproved peptides, including BPC-157 and TB-500, be compounded by licensed pharmacies [1]. That move may raise demand worldwide. It also shows that India's drug framework was built for physical supply chains, not online wellness sales.

Regulatory challenges

• Legal vacuum online: India's draft e-pharmacy rules, G.S.R. 817(E) of August 2018, are still not final, and the matter is pending in the courts [3].
• Outdated parent law: the Drugs and Cosmetics Act, 1940 came long before the internet. The Drugs, Medical Devices and Cosmetics Bill, 2022 would require a licence to sell drugs online [4], but it is still not law.
• Evidence gap: wellness peptides mostly have animal or early-stage data. Even the US route leaves them unapproved [1]. A licensed seller can make sure a product is pure, but only clinical trials show that it works.
• Surveillance blind spot: the national drug survey tested 47,954 samples and found 3.16% not of standard quality and 0.0245% spurious [2]. Those samples came from shops and government stores, so peptides sold online or in gyms were never tested.
• Federal capacity gap: CDSCO has a small staff. Retail and online enforcement depends on State Drug Controllers, whose capacity varies from state to state.
• Global falsification risk: WHO estimates that 1 in 10 medical products in low- and middle-income countries is substandard or falsified [5]. Countries spend about US$30.5 billion a year on such products [6].

Reforms

• Finalise the e-pharmacy rules, covering registration, inspection and a ban on advertising [3].
• Enact the 2022 Bill and name peptides and other "wellness injectables" as a prescription-only class [4].
• Run test-purchase surveys of peptides bought from websites and gyms, using the national survey as a model [2].
• Report test failures to WHO's Global Surveillance and Monitoring System, where reported incidents rose nearly 60% in two years [7].
• Keep approval evidence-first under the New Drugs and Clinical Trials Rules, 2019, with no ministerial shortcut like enforcement discretion.
• Fund State Drug Controllers properly and track online drug sales digitally.

India's gaps are a law written before the internet, rules stuck in draft and surveillance that misses online sales. Peptides make all three more urgent. Enacting the online-sale laws and keeping the burden of proof on sellers would let patients reach new therapies safely. This supports the right to health under Article 21 and SDG 3.8 on access to safe medicines.